Search Results

Dyadic International Inc. (“Dyadic”, or the “Company”) (Nasdaq: DYAI) and Cygnus Technologies®, part of Maravai LifeSciences® (Nasdaq: MRVI), announced today a strategic partnership for the quantification of Host Cell Proteins (“HCP”) from the proprietary and patented C1-cells filamentous fungus Thermothelomyces heterothallica, (formerly Myceliophthora thermophila).

Cygnus Technologies, part of Maravai LifeSciences, the leading product and services provider for the detection and characterization of process-related impurities in biopharmaceuticals, received a 2023 R&D 100 Award from R&D World Magazine in the Analytical/Test category for the MockV® RVLP Kit.

VIVEX Biologics, Inc., a leading regenerative medicine company specializing in the development of naturally sourced treatments, announced that the Centers for Medicare and Medicaid Services has assigned a Q-code for its CYGNUS® Dual amniotic allograft product.

Bio-Techne Corporation and Cygnus Technologies, part of Maravai LifeSciences, announced the launch of the Simple Plex™ HEK 293 HCP 3G assay for automated process impurity testing on the Ella™ immunoassay platform.

The FDA’s guidance on AI in drug development points to potentially life-threatening consequences of the technology, highlighting the importance of providing the regulator with detailed information regarding models’ development and maintenance.